SNDX - CIK 0001395937
The table below shows Syndax Pharmaceuticals Inc's cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$322.98M | -$274.90M | -$160.60M | -$133.68M | $29.13M | -$71.26M |
| Capital expenditure | $187.00K | $0.00 | $0.00 | $0.00 | $129.00K | $0.00 |
| Investing cash flow | $290.04M | -$219.78M | $117.61M | -$186.19M | -$40.87M | -$142.53M |
| Dividends paid | - | - | - | - | - |
Syndax Pharmaceuticals Inc reported operating cash flow of -$322.98M for fiscal year 2025. That is down 17.5% from -$274.90M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$35.16M (FY 2016) to -$322.98M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $13.68M | $353.37M | $264.13M | $172.25M | $118.46M | $304.42M |